Biomarkers for the clinical management of breast cancer: International perspective. Issue 1 (8th February 2013)

• Record Type: Journal Article
• Authors: Patani, Neill; Martin, Lesley‐Ann; Dowsett, Mitch
• Is Part Of: International journal of cancer. Volume 133:Issue 1(2013:Jul. 01)
• Page Start: 1
• Page End: 13
• Publication Date: 2013-02-08
• Subjects: breast cancer -- biomarkers -- predicitive -- prognostic -- personalized treatment -- quality assurance -- cost effectiveness -- availability -- developing countries; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.27997
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : The higher incidence of breast cancer in developed countries has been tempered by reductions in mortality, largely attributable to mammographic screening programmes and advances in adjuvant therapy. Optimal systemic management requires consideration of clinical, pathological and biological parameters. Oestrogen receptor alpha (ERα), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) are established biomarkers evaluated at diagnosis, which identify cardinal subtypes of breast cancer. Their prognostic and predictive utility effectively guides systemic treatment with endocrine, anti‐HER2 and chemotherapy. Hence, accurate and reliable determination remains of paramount importance. However, the goals of personalized medicine and targeted therapies demand further information regarding residual risk and potential benefit of additional treatments in specific circumstances. The need for biomarkers which are fit for purpose, and the demands placed upon them, is therefore expected to increase. Technological advances, in particular high‐throughput global gene expression profiling, have generated multi‐gene signatures providing further prognostic and predictive information. The rational integration of routinely evaluated clinico‐pathological parameters with key indicators of biological activity, such as proliferation markers, also provides a ready opportunity to improve the information available to guide systemic therapy decisions. The additional value of such information and its proper place in patient management is currently under evaluation in prospective clinical trials. Expanding the utility of biomarkers to lower resource settings requires an emphasis on cost effectiveness, quality assurance and possible international variations in tumor biology; the potential for improved clinical outcomes should be justified against logistical and economic considerations.